Home  /  Resource Library  /  A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL

A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: Preliminary results for patients with CLL/SLL

ICML 2023